• 제목/요약/키워드: antihemophilic factor IX

검색결과 3건 처리시간 0.017초

Enhanced Virus Safety of a Solvent/Detergent-Treated Anti-hemophilic Factor IX Concentrate by Dry-Heat Treatment

  • Shin Jeong-Sup;Choi Yong-Woon;Sung Hark-Mo;Ryu Yeon-Woo;Kim In-Seop
    • Biotechnology and Bioprocess Engineering:BBE
    • /
    • 제11권1호
    • /
    • pp.19-25
    • /
    • 2006
  • With particular regards to the hepatitis A virus (HAV), a terminal dry-heat treatment ($100^{\circ}C$ for 30 min) process, following lyophilization, was developed to improve the virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate. The loss of factor IX activity during dry-heat treatment was of about 3%, as estimated by a clotting assay. No substantial changes were observed in the physical and biochemical characteristics of the dry-heat-treated factor IX compared with those of the factor IX before dry-heat treatment. The dry-heat-treated factor IX was stable for up to 24 months at $4^{\circ}C$, The dry-heat treatment after lyophilization was an effective process for inactivating viruses. The HAV and murine encephalomyocarditis virus (EMCV) were completely inactivated to below detectable levels within 10 min of the dry-heat treatment. Porcine parvovirus (PPV) and bovine herpes virus (BHV) were potentially sensitive to the treatment. The log reduction factors achieved during lyophilization and dry-heat treatment were ${\ge}5.60$ for HAV, ${\ge}6.08$ for EMCV, 2.64 for PPV, and 3.59 for BHV. These results indicate that dry-heat treatment improves the virus safety of factor IX concentrates, without destroying the activity. Moreover, the treatment represents an effective measure for the inactivation of non-lipid enveloped viruses, in particular HAV, which is resistant to solvent/detergent treatment.

사람 혈장으로부터 고순도 혈액응고 제9인자의 산업적 생산 (Industrial-Scale Production of High-Purity Antihemophilic Factor IX from Human Plasma)

  • 강용;최용운;성학모;손기환;신정섭;김인섭
    • KSBB Journal
    • /
    • 제23권1호
    • /
    • pp.37-43
    • /
    • 2008
  • (주)녹십자는 1986년 "훽나인"을 B형 혈우병 치료제로 제조품목허가를 받아 B형 혈우병치료제 공급을 시작하였다. 또한 1991년 New York Blood Center에서 selvent/detergent 바이러스 불활화 방법을 도입하여 제조공정에 추가한 후 혈액유래 바이러스로부터 안전한 제품을 생산하여 왔다. 하지만 이 제품은 혈액응고 제2인자, 제7인자, 제10인자가 함유된 제9인자 복합체로, 정맥 혈전증과 파종성 혈관내응고병증 같은 혈전형성 부작용이 일어날 가능성이 있어, 훽나인보다 순도, 유효성, 바이러스 안전성이 우수한 제품의 개발이 필요하였다. 이를 위해 고순도 제9인자 제제인 "GreenNine VF" 제조공정을 개발하였다. GreenNine VF 제조공정은 기존의 훽나인 생산 공정에 heparin 친화성 크로마토그래피와 양이온 크로마토그래피가 추가된 공정으로, 바이러스 안전성을 증진시키기 위한 바이러스 필터 공정도 포함하고 있다. 이러한 공정에 의해서 산업적 규모로 생산된 GreenNine VF는 훽나인에 비해 순도와 바이러스 안전성이 월등히 높은 것으로 확인되었다. 또한 고순도 혈액응고 제9인자 제제인 Mononine, Octanyne, Berinin HS, Immunine STIM plus 600보다 순도가 더 높았다. Cryo-poor plasma 1,600 L를 원료로 사용했을 때 1 batch 당 250IU 분병제품 2,400병 이상, 500 IU 분병제품 1,200병 이상을 생산할 수 있었다.

Improvement of Virus Safety of an Antihemophilc Factor IX by Virus Filtration Process

  • Kim, In-Seop;Choi, Yong-Woon;Kang, Yong;Sung, Hark-Mo;Sohn, Ki-Whan;Kim, Yong-Sung
    • Journal of Microbiology and Biotechnology
    • /
    • 제18권7호
    • /
    • pp.1317-1325
    • /
    • 2008
  • Viral safety is an important prerequisite for clinical preparations of plasma-derived pharmaceuticals. One potential way to increase the safety of therapeutic biological products is the use of a virus-retentive filter. In order to increase the viral safety of human antihemophilic factor IX, particularly in regard to non-enveloped viruses, a virus removal process using a polyvinylidene fluoride membrane filter (Viresolve NFP) has been optimized. The most critical factor affecting the filtration efficiency was operating pH and the optimum pH was 6 or 7. Flow rate increased with increasing operating pressure and temperature. Recovery yield in the optimized production-scale process was 96%. No substantial changes were observed in the physical and biochemical characteristics of the filtered factor IX in comparison with those before filtration. A 47-mm disk membrane filter was used to simulate the process performance of the production-scale cartridges and to test if it could remove several experimental model viruses for human pathogenic viruses, including human hepatitis A virus (HAV), porcine parvovirus (PPV), murine encephalomyocarditis virus (EMCV), human immunodeficiency virus type 1 (HIV), bovine viral diarrhea virus (BVDV), and bovine herpes virus (BHV). Non-enveloped viruses (HAV, PPV, and EMCV) as well as enveloped viruses (HIV, BVDV, and BHV) were completely removed during filtration. The log reduction factors achieved were $\geq$6.12 for HAV, $\geq$4.28 for PPV, $\geq$5.33 for EMCV, $\geq$5.51 for HIV, $\geq$5.17 for BVDV, and $\geq$5.75 for BHV. These results indicate that the virus filtration process successfully improved the viral safety of factor IX.